<DOC>
	<DOCNO>NCT03084939</DOCNO>
	<brief_summary>This Phase III , randomize , multicenter , two-arm , open-label study design evaluate safety efficacy trastuzumab emtansine compare lapatinib + capecitabine Chinese participant HER2-positive , unresectable locally advanced breast cancer ( LABC ) metastatic breast cancer ( MBC ) receive prior trastuzumab-based therapy . A total approximately 400 participant enrolled China . Eligible participant randomize 3:1 ratio receive either trastuzumab emtansine control ( lapatinib + capecitabine ) .</brief_summary>
	<brief_title>Efficacy Safety Trastuzumab Emtansine Chinese Participants With Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Aged &gt; /= 18 year Prospective centrally assess HER2positive disease ( i.e. , immunohistochemistry [ IHC ] 3+ and/or gene amplify [ HER2 Chromosome 17 [ CEP 17 ] ratio &gt; /= 2 ] ) situ hybridization ( ISH ) use archival paraffinembedded tumor tissue Histologically cytologically confirm invasive breast cancer ( BC ) : incurable , unresectable LABC previously treat multimodality therapy MBC Prior treatment BC adjuvant , unresectable locally advanced metastatic setting must include : taxane , alone combination another agent , trastuzumab , alone combination another agent adjuvant , unresectable locally advanced metastatic setting Documented progression incurable , unresectable LABC MBC , define investigator : progression must occur recent treatment LABC MBC within 6 month complete adjuvant therapy Measurable and/or nonmeasurable disease , accord Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 definition : CNSonly disease exclude Left ventricular ejection fraction ( LVEF ) &gt; /=50 % either echocardiogram multiplegated acquisition Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Adequate organ function evidence laboratory result within 30 day prior randomization For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use nonhormonal contraceptive method result failure rate &lt; 1 % per year treatment period least 7 month last dose study drug For men : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure ( use condom plus additional contraceptive method together result failure rate &lt; 1 % per year ) agreement refrain donate sperm treatment period least 7 month last dose study drug History treatment trastuzumab emtansine Prior treatment lapatinib capecitabine Peripheral neuropathy Grade &gt; /= 3 per National Cancer Institute Common Terminology Criteria Adverse Events Version 4.0 ( NCI CTCAE v4.0 ) History malignancy within previous 5 year , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage 1 uterine cancer , synchronous previously diagnose HER2positive BC , cancer similar curative outcome mention History receive anticancer drug/biologic investigational treatment within 21 day prior randomization , except hormone therapy give 7 day prior randomization History radiation therapy within 14 day randomization Brain metastasis untreated , symptomatic , progressive , require therapy radiation , surgery corticosteroid therapy control symptom brain metastasis within 30 day randomization History exposure cumulative dos anthracyclines : Doxorubicin &gt; 500 milligram per square meter ( mg/m^2 ) , Epirubucin &gt; 720 mg/m^2 , Mitoxantrone &gt; 120 mg/m^2 Current severe , uncontrolled systemic disease ( e.g. , clinically significant cardiovascular , pulmonary , metabolic disease ) Pregnancy lactation Currently know active infection HIV , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) Presence condition could affect gastrointestinal absorption History intolerance ( include Grade 3 4 infusion reaction ) hypersensitivity trastuzumab murine protein Known hypersensitivity 5fluorouracil know dihydropyrimidine dehydrogenase deficiency Current treatment sorivudine chemically related analog</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>